小干扰RNA对脂蛋白(a)的影响：一项系统评价
Small interfering RNA effect on lipoprotein(a): a systematic review.
作者信息
Almaadawy Omar, Hesn Mohamed Mar'ey, Elsalamony Yomna Ayman, Abobakr Omar Ayman, Elshimy Abdelrahman Hossam, Abulkhair Khaled Alsayed, Negm Mahmoud Mohamed, Shaban Ahmed Yasser, Bene-Alhasan Yakubu, Annie Frank, Belcher Adam, Elashery Ahmed Ramy
机构信息
Internal Medicine Department, MedStar Health, 201 E. University Pkwy, Baltimore, MD, 21218, USA.
Faculty of Medicine, Al Azhar University, New Damietta, Egypt.
出版信息
Egypt Heart J. 2025 May 8;77(1):44. doi: 10.1186/s43044-025-00635-1.
BACKGROUND
This systematic review investigates the effect of small interfering RNA (siRNA) therapies on lipoprotein(a) [Lp(a)] levels. The purpose is to evaluate the outcomes of recent randomized controlled trials (RCTs) involving siRNA treatments aimed at lowering Lp(a) levels, a known cardiovascular risk factor.
METHODS
A comprehensive search across multiple databases was conducted, identifying 20 published and ongoing RCTs that examined the effects of siRNA therapies such as inclisiran, olpasiran, and SLN360 on Lp(a) levels. The included studies were analyzed to assess Lp(a) reductions and other lipid-related outcomes.
RESULTS
The RCTs demonstrated significant reductions in Lp(a) levels following siRNA therapy. Additional reductions were noted in LDL-c and apolipoprotein B levels. Side effects were typically mild, including injection site reactions.
CONCLUSIONS
siRNA therapies show promise in effectively lowering Lp(a) levels, with minimal adverse effects. However, further research is required to establish their long-term safety and efficacy.
背景
本系统评价研究了小干扰RNA（siRNA）疗法对脂蛋白(a) [Lp(a)]水平的影响。目的是评估近期涉及旨在降低Lp(a)水平（一种已知的心血管危险因素）的siRNA治疗的随机对照试验（RCT）结果。
方法
对多个数据库进行了全面检索，确定了20项已发表和正在进行的RCT，这些试验研究了inclisiran、olpasiran和SLN360等siRNA疗法对Lp(a)水平的影响。对纳入的研究进行分析，以评估Lp(a)的降低情况和其他与脂质相关的结果。
结果
RCT表明，siRNA治疗后Lp(a)水平显著降低。低密度脂蛋白胆固醇（LDL-c）和载脂蛋白B水平也有额外降低。副作用通常较轻，包括注射部位反应。
结论
siRNA疗法有望有效降低Lp(a)水平，且副作用最小。然而，需要进一步研究以确定其长期安全性和有效性。
Zotero 插件